Filtered By:
Specialty: Biotechnology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 393 results found since Jan 2013.

Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery.
In conclusion, the application of CPP-siRNA/YSA-NB with ultrasound may provide a strategy for the selective and efficient delivery of siRNA. PMID: 26492155 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - October 19, 2015 Category: Biotechnology Authors: Xie X, Yang Y, Lin W, Liu H, Liu H, Yang Y, Chen Y, Fu X, Deng J Tags: Colloids Surf B Biointerfaces Source Type: research

Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA-PLGA/CSO conjugate micelles.
Abstract Biodegradable and biocompatible poly(d,l-lactic-co-glycolic acid) (PLGA)was conjugated to the 5'-thiol end of signal transducer and activator of transcription 3 (STAT3) small interfering RNA (STAT3-siRNA) via a disulfide bond. In aqueous environments, these siRNA-PLGA conjugates can spontaneously form core/shell type spherical micelles with a particle size of about 200nm. A biodegradable, low molecular weight cationic polymer, chitosan oligosaccharide (CSO), was added to the siRNA-PLGA micelles at different nitrogen to phosphate (N/P) ratios to form stable, spherical siRNA-PLGA/CSO micelles with sizes of ...
Source: Colloids and Surfaces - January 28, 2015 Category: Biotechnology Authors: Zhao Y, Zheng C, Zhang L, Chen Y, Ye Y, Zhao M Tags: Colloids Surf B Biointerfaces Source Type: research

Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
The objective of this work consists in formulating and optimizing the encapsulation of siRNA into lipid nanocapsules (LNCs) for efficient gene therapy on melanoma cells. SiRNA LNCs were prepared from DOTAP/DOPE lipoplexes, and the siRNA dose and lipid/siRNA charge ratio were assayed to improve the stability and encapsulation yield. Cryo-TEM imaging of the siRNA lipoplexes and LNC morphology revealed a specific organization of the siRNA DOTAP/DOPE lipoplexes as well as specific lipid microstructures. No cytotoxicity of the siRNA LNCs against the melanoma SK-Mel28 cell line was observed at concentrations of up to 500 ng/mL s...
Source: Biotechnology Journal - September 26, 2014 Category: Biotechnology Authors: Resnier P, LeQuinio P, Lautram N, André E, Gaillard C, Bastiat G, Benoit JP, Passirani C Tags: Biotechnol J Source Type: research

Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy.
In conclusion, the application of siRNA-CPPs/TML under an AC magnetic field represents a new strategy for the selective and efficient delivery of siRNA. PMID: 27429294 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - July 1, 2016 Category: Biotechnology Authors: Yang Y, Xie X, Xu X, Xia X, Wang H, Li L, Dong W, Ma P, Yang Y, Liu Y, Mei X Tags: Colloids Surf B Biointerfaces Source Type: research

Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
In conclusion, layer-by-layer chitosan coated AuNP can be developed as a carrier for iontophoretic delivery of STAT3 siRNA to treat melanoma. PMID: 27318964 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - June 2, 2016 Category: Biotechnology Authors: Labala S, Jose A, Venuganti VV Tags: Colloids Surf B Biointerfaces Source Type: research

Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
Abstract Co-delivery of chemotherapy drugs and siRNA for cancer therapy has achieved remarkable results according to synergistic/combined antitumor effects, and is recognized as a promising therapeutic modality. However, little attention has been paid to the extremely complex mechanisms of chemotherapy drug-siRNA pairs during co-delivery process. Proper selection of chemotherapy drug-siRNA pairs is beneficial for achieving desirable cancer therapeutic effects. Exploring the inherent principles during chemotherapy drug-siRNA pair selection for co-delivery would greatly enhanced therapeutic efficiency. To achieve id...
Source: Colloids and Surfaces - June 8, 2017 Category: Biotechnology Authors: Wang M, Wang J, Li B, Meng L, Tian Z Tags: Colloids Surf B Biointerfaces Source Type: research

Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery.
Abstract Small interfering RNAs (siRNA) are short nucleic acid fragments of about 20-27 nucleotides, which can inhibit the expression of specific genes. siRNA based RNAi technology has emerged as a promising method for the treatment of a variety of diseases. However, a major limitation in the therapeutic use of siRNA is its rapid degradation in plasma and cellular cytoplasm, resulting in short half-life. In addition, as siRNA molecules cannot penetrate into the cell efficiently, it is required to use a carrier system for its delivery. In this work, chemically and morphologically different calcium phosphate (CaP) n...
Source: Colloids and Surfaces - June 27, 2017 Category: Biotechnology Authors: Bakan F, Kara G, Cokol Cakmak M, Cokol M, Denkbas EB Tags: Colloids Surf B Biointerfaces Source Type: research

Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
In conclusion, our novel PEGylated liposomes have high potential for systemic delivery of siRNA and can improve in vivo stability of free siRNA and also siRNA lipoplexes. PMID: 29475393 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - February 26, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Local Silencing of Connective Tissue Growth Factor by siRNA/Peptide Improves Dermal Collagen Arrangements
Conclusion:CTGF expression was down-regulated to 40% of control by CTGF siRNA/KALA (1:24) complexes (p <  0.01) and collagen lattice contraction was inhibited. However, down-regulated of CTGF by CTGF siRNA/MPG∆NLS complexes was not statistically significant. CTGF KALA-treated wound appeared with well formed-basket weave pattern of collagen fibrils with mean diameter of 128  ± 22 nm (n = 821). Mismatch siRNA/KALA-treated wound showed a high frequency of parallel small diameter fibrils (mean 90 ± 20 nm, n = 563).Conclusion:Controlling over-expression of CTGF by peptide-mediated siRNA delivery cou...
Source: Tissue Engineering and Regenerative Medicine - November 14, 2018 Category: Biotechnology Source Type: research

In vivo evaluation and Alzheimer's disease treatment outcome of siRNA loaded dual targeting drug delivery system.
Abstract To deliver drugs to treat Alzheimer's disease (AD), nanoparticles should firstly penetrate through blood brain barrier, and then target neurons. Recently, we developed an Apo A-I and NL4 dual modified nanoparticle (ANNP) to deliver beta-amyloid converting enzyme 1 (BACE1) siRNA. Although promising in vitro results were obtained, the in vivo performance was not clear. Therefore, in this study, we further evaluated the in vivo neuroprotective effect and toxicity of the ANNP/siRNA. The ANNP/siRNA was 80.6 nm with good stability when incubated with serum. The ANNP/siRNA could target both bEnd.3 and PC12 cells...
Source: Current Pharmaceutical Biotechnology - February 4, 2019 Category: Biotechnology Authors: Zhang C, Shen L, Gu Z, Liu X, Lin H Tags: Curr Pharm Biotechnol Source Type: research

Polyelectrolyte complexes of hTERT siRNA and polyethyleneimine: Effect of degree of PEG grafting on biological and cellular activity.
Authors: Safari F, Tamaddon AM, Zarghami N, Abolmali S, Akbarzadeh A Abstract Gene silencing by siRNA (short interfering RNA)-targeted human telomerase reverse transcriptase (hTERT) is considered a successful strategy for cancer gene therapy. Polyelectrolyte complexes (PEC) of siRNA and cationic polymers such as polyethyleneimine (PEI) have been widely used for cellular transfection; however, they demonstrate some disadvantages such as cytotoxicity and extracellular matrix restrictions. PEG grafting technology was used in an attempt to improve the biocompatibility of PECs. Considering that this technology may compr...
Source: Artificial Cells, Nanomedicine and Biotechnology - December 12, 2015 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells.
Abstract The aim of this study is to improve hydrocolloid stability and siRNA transfection ability of a reduced graphene oxide (rGO) based nano-carrier using a phospholipid-based amphiphilic polymer (PL-PEG) and cell penetrating peptide (CPPs). The dual functionalized nano-carrier is comprehensively characterized for its chemical structure, size, surface charge and morphology as well as thermal stability. The nano-carrier cytocompatibility, siRNA condensation ability both in the presence and absence of enzyme, endosomal buffering capacity, cellular uptake and intracellular localization are also assessed. The siRNA...
Source: Colloids and Surfaces - August 11, 2016 Category: Biotechnology Authors: Imani R, Shao W, Taherkhani S, Emami SH, Prakash S, Faghihi S Tags: Colloids Surf B Biointerfaces Source Type: research

Study and Evaluation of the Potential of Lipid Nanocarriers for Transdermal Delivery of siRNA.
In this study, we used 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or lipofectamine to prepare a nanocarrier for delivering siRNA against glyceraldehyde 3-phosphate dehydrogenase (GAPDH); GAPDH expression was then evaluated at the cellular level. In addition, a dermal transport assay was designed and implemented to evaluate the penetration and delivery efficacy of siRNA in pig skin using lipid nanocarriers. The delivery of siRNA with the use of a lipid nanocarrier was significantly better than the delivery of siRNA without it. Thus, Our findings identify lipid nanocarriers as excellent candidates for the transdermal d...
Source: Biotechnology Journal - July 16, 2020 Category: Biotechnology Authors: Lee K, Min D, Choi Y, Kim J, Yoon S, Jang J, Park S, Tanaka M, Cho YW, Koo HJ, Jeon H, Choi J Tags: Biotechnol J Source Type: research

Development of a specific siRNA delivery system into HeLa cells using an IgG-binding fusion protein.
In this study, two repeats of Fc binding domain of protein G (C2) were used to introduce a specific antibody to PEI-based carrier of siRNA. In addition, we used the double-stranded RNA binding domain (DRBD) that can bind to siRNA. The complex, consisting of PEI, siRNA and constructed fusion protein, TrxC2DRBD including C2 and DRBD domains, could protect siRNA from RNase degradation. Furthermore, cell specific siRNA delivery into HeLa cells could be performed by the complex fusion with specific antibodies via C2 domain. PMID: 23907669 [PubMed - as supplied by publisher]
Source: Biotechnology Letters - August 2, 2013 Category: Biotechnology Authors: Bae J, Mie M, Kobatake E Tags: Biotechnol Lett Source Type: research

Co-delivery of doxorubicin and siRNA by a simplified platform with oligodeoxynucleotides as a drug carrier.
In this study, a simplified and effective system for the co-loading and intracellular co-delivery of doxorubicin (Dox) and siRNA was developed. Oligodeoxynucleotides with CGA repeating units (CGA-ODNs) were introduced to load Dox. The loading mechanism was based on the ability of Dox to intercalate within double-stranded 5'-GC-3' or 5'-CG-3' sequences. Poly(ethyleneimine) (PEI) was used to condense siRNA and Dox loaded CGA-ODNs (CGA-ODNs-Dox) to obtain Dox and siRNA co-loaded nanocomplexes (PEI/CGA-ODNs-Dox&siRNA, PDR). The cellular uptake of PDR in A549 and HepG2 cells was 39.52% and 36.78%, respectively, indicating t...
Source: Colloids and Surfaces - January 14, 2015 Category: Biotechnology Authors: Liu T, Wang M, Wang T, Yao Y, Zhang N Tags: Colloids Surf B Biointerfaces Source Type: research